Skip to main content
. 2020 Jan 25;9(2):340. doi: 10.3390/jcm9020340

Figure 5.

Figure 5

Effect of MDL 72527 treatment on diabetes-induced RGC loss. (A–D) Immunostaining of retinal cryostat sections using Brn3a antibody showing a reduced number of Brn3a positive RGCs in the diabetic retina (16 weeks), compared to control. Treatment with MDL 72527 improved the survival of Brn3a positive cells. (E) Quantitative analysis demonstrating significant loss of Brn3a-positive cells in the GCL in response to diabetes. Treatment with MDL 72527 protected against the diabetes-induced RGC loss. (F–I) Immunostaining using Tuj1 marker showing the axonal loss in diabetic retina compared to controls. MDL 72527 treatment reduced axonal degeneration in the diabetic retina. Treatment with MDL 72527 markedly improved Tuj1 levels in diabetic retina. N = 5–6 per group were included in the experiment and representative images are shown. Data are presented as mean ± SD. Data are presented as mean ± SD. # p < 0.01. Scale bar 50 µm.